Hims & Hers Health Surges 2.88% on $2.11 Billion Volume, Climbs to 98th in U.S. Dollar Volume Rankings

, 2025, , ranking 98th among U.S. stocks by dollar volume. The stock's performance followed renewed investor focus on its digital healthcare platform expansion and strategic partnerships in men’s wellness. Analysts noted improved market sentiment amid broader sector rotations into telehealth and direct-to-consumer services.

Recent developments highlighted HIMS's efforts to scale its AI-driven diagnostic tools and subscription-based treatment models. A key catalyst was a partnership with a major U.S. pharmacy chain to streamline access to personalized skincare and hormone therapy programs. These moves align with the company’s 2025 roadmap to diversify revenue streams beyond its core grooming and sexual health offerings.

Market participants also observed a shift in institutional positioning, with several funds increasing exposure to HIMS following its Q2 2025 earnings report. , . Despite this, the stock’s technical indicators suggest short-term momentum remains intact.

To set up this back-test accurately, I need to clarify: (1) the universe of tradable stocks (e.g., all U.S. equities or a specific index), (2) whether to use closing prices for entries and exits, and (3) whether to account for transaction costs. Once parameters are defined, the back-test data-gathering plan can be finalized.